With the support of

An initiative of

INSTITUT
JULES BORDET
INSTITUUT

BREAST CANCER DEBATE
OF THE YEAR

THE HOTEL - Grand Ballroom 1st Floor
Boulevard de Waterloo 38, 1000 Brussels
Friday January 25, 2019

Program

Debate on controversies in the management of luminal breast cancer
An education activity of the Breast Cancer Task Force of the BSMO

Organizing Committee:
Ahmad Awada (Institut Jules Bordet, Brussels), Hans Wildiers (UZ Leuven) and Peter Vuylsteke (CHU UCL Namur)

19.00-19.40 Welcome and buffet
19.40-19.45 Introduction:
Ahmad Awada (Institut Jules Bordet) and Hans Wildiers (UZ Leuven)

19.45-20.15 Should adjuvant anthracyclines always be part of the chemo-regimen in early stage luminal breast cancer?
In favour: Caroline Duhem, CHL (10 min)
Against: Hans Wildiers, Leuven (10 min)
Discussion: all (10 min)

20.15-20.45 Should we perform gene expression profiling in all patients with pT2N0/1 luminal breast cancers?
In favour: Christos Sotiriou, Brussels (10 min)
Against: Patrick Neven, Leuven (10 min)
Discussion: All (10 min)

20.45-21.00 Coffee Break

21.00-21.30 Should PIK3CA be tested in metastatic luminal breast cancer?
In favour: Peter Vuylsteke, Namur (10 min)
Against: Ahmad Awada, Brussels (10 min)
Discussion: All (10 min)

21.30-22.00 Should upfront chemotherapy be the treatment of choice for patients with metastatic triple positive breast cancer?
In favour: Hannelore Denys, Gent (10 min)
Against: Jeroen Mebis, Hasselt (10 min)
Discussion: All (10 min)

22.00-22.15 Conclusions and take home messages: Peter Vuylsteke, CHU UCL Namur